EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN¿DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES A Nooka; A Lesokhin; M Mohty; R Niesvizky; C Maisel; B Arnulf; S Larson; A Varshavsky-Yanovsky; X Leleu; L Karlin; D Vesole; N Bahlis; CF Larrea; N Raje; E Leip; U Conte; M Elmeliegy; A Viqueira; V Blunk; S Manier;

ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM THE MAGNETISMM-3 STUDY M Mohty; M Tomasson; B Arnulf; N Bahlis; M Prince; R Niesvizky; P Rodrgue-Otero; J Martine-Lopez; G Koehne; Y Jethava; A Gabayan; D Stevens; A Nooka; N Raje; S Iida; E Leip; U Conte; A Czibere; A Viqueira; V Blunk; A Lesokhin;

A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM): INITIAL SAFETY RESULTS FOR MAGNETISMM-3 AM Lesokhin; B Arnulf; R Niesvizky; M Mohty; NJ Bahlis; MH Tomasson; P Rodrguez-Otero; H Quach; NS Raje; S Iida; M Raab; A Czibere; S Sullivan; E Leip; A Viqueira; V Blunk; X Leleu;